Vaxcyte (PCVX) said Thursday it has launched a public offering of its common stock and pre-funded warrants worth $500 million.
Underwriters are expected to be given a 30-day option to buy up to an additional $75 million in shares.
Shares were down nearly 1% in recent after-hours trading.